Importantly, this is the first evidence showing that TAX1BP1 can be as a novel regulatory target to attenuate the lung inflammation.
Activated leukocyte cell adhesion molecule (ALCAM) plays an important role in T cell activation and immune response, but the role of ALCAM in allergic rhinitis (AR) remains unclear. https://www.selleckchem.com/products/glumetinib.html The objective of the current study was to validate serum ALCAM as a biomarker in assessing disease severity and predicting the efficacy of sublingual immunotherapy (SLIT) in AR patients.
We recruited 40 healthy controls (HC group), 38 mild AR patients (MAR group) and 80 moderate-severe AR patients (MSAR group) in this study. Serum levels of ALCAM were determined by ELISA, and the association between ALCAM levels and disease severity was evaluated. In the MSAR group, 68 patients underwent and finished 3-years of SLIT, and were divided into effective group and ineffective group, the relationship between ALCAM levels and efficacy of SLIT was exampled.
ALCAM levels were elevated in the serum of AR patients in comparison with HC. Moreover, serum ALCAM concentrations were higher in MSAR group than in MAR group and HC group, and levels of ALCAM significantly correlated with AR total nasal symptom score (TNSS) (r = 0.330, P < 0.001), visual analogue scale (VAS) (r = 0.387, P < 0.001) and serum total IgE levels (r = 0.442, P < 0.001). In the effective group, the ALCAM levels were significantly lower than in the ineffective group. Receiver operating characteristic (ROC) curve exhibited good accuracy for predicting clinical efficacy of SLIT (area under the curve = 0.805, P < 0.001).
The serum ALCAM maybe a novel biomarker for assessing disease severity and predicting clinical efficacy of SLIT in AR patients.
The serum ALCAM maybe a novel biomarker for assessing disease severity and predicting clinical efficacy of SLIT in AR patients.
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and is responsible for 45-50% of primary glomerular diseases in China. We are essentially dependent on the degree of proteinuria to determine prognosis and it has been reported that histopathologic lesions are risk factors for the progression of IgAN. The aim of this study was to investigate the clinicopathologic features and prognosis of IgAN with C1q deposition in adult Chinese patients.
The patients of primary IgAN diagnosed by renal biopsy from January 2002 to December 2018 at the Second Hospital of Shanxi Medical University were retrospectively analyzed and divided into C1q deposit group and C1q negative group according to glomerular immunofluorescence examination. We evaluated their serologic and histopathologic findings. We collected data of patients during January 1, 2015 to December 31, 2018 and performed the clinical follow-up until the patient's estimated glomerular filtration rate (eGFR) decreased by more than 30unction and contributes to a poor renal prognosis in adult IgAN patients.
We aimed to study the effects and the underlying mechanisms of Diosmetin (DIOS) in rats with sepsis-induced acute kidney injury (AKI).
The AKI model in RMCs was induced using LPS, and the cells were then treated with DIOS. Cell viability, apoptosis, inflammatory response, and antioxidant were measured using MTT, Flow cytometry, ELISA, and Lucigenin assay, respectively. The correlation between TUG1 and Nrf2 was confirmed by RNA pull-down and RNA immunoprecipitation. Real-time quantitative PCR and Western blot were performed to detect the expressions of gene and proteins during the development of AKI. The effects of lncRNA-TUG1 silencing and Nrf2 silencing on cell physiological functions were detected. Moreover, a rat sepsis-induced AKI model followed by Hematoxylin & Eosin (H&E) and immunofluorescence staining were performed.
The experimental concentration of DIOS was determined to be 20μM. After LPS treatment, the activity of RMCs was decreased, the apoptosis rate, inflammation and oxidative stress damage were increased, moreover, the expression of Nrf2/HO-1 signal axis was inhibited and caspase-3 was activated. However, DIOS significantly reversed these effects caused by LPS treatment, and increased the expression of lncRNA-TUG1, but lncRNA-TUG1 silencing effectively reversed the effects of DIOS. In addition, lncRNA-TUG1 was found to interact with Nrf2. Overexpression of TUG1 could reduce the damage of LPS caused to cell physiological functions, which were reversed by siNrf2. Thus, DIOS treatment could improve the physiological and pathological damages of renal tissues in AKI rats.
DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.
DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.The present study aimed to investigate the protective effects and mechanisms of Didymin from Mentha spicata on non-alcoholic fatty liver disease (NAFLD) induced by dexamethasone and high-fat diet (DEX/HFD) in C57BL/6J ****. Briefly, **** were acclimated for 5 days and then subjected to DEX/HFD from days 5 to 28; meanwhile, the animals were treated with Didymin or Silibinin from days 12 to 28. Key indicators of NAFLD were then detected, including the pathological changes of liver tissues, serum biochemical indicators, inflammation, oxidative stress, apoptosis and lipid metabolism. Besides, the expressions of pivotal genes and proteins of the TLR4/NF-κB and PI3K/Akt pathways were examined to further elucidate the mechanisms of Didymin. The results demonstrated that Didymin significantly extenuated hepatocyte damage and lipid disorder. Moreover, Didymin markedly decreased hepatocyte apoptosis by regulating the expressions of B-cell lymphoma-2 (Bcl-2) family and the expressions of the caspase family. Further study elucidated that Didymin decreased the expressions of toll-like receptor 4 (TLR4), as well as the phosphorylation of inhibitor of nuclear factor kappa-B (IκB) and nuclear factor kappa-B p65 (NF-κB p65), suggesting the inhibition of Didymin on the TLR4/NF-κB pathway. Similarly, the PI3K/Akt pathway was also inhibited by Didymin, as evidenced by the decrease in the phosphorylation levels of PI3K and Akt. In summary, this study indicates that Didymin mitigates NAFLD by alleviating lipidosis and suppressing the TLR4/NF-κB and PI3K/Akt pathways, which may be a potential natural medicine for the treatment of NAFLD.
Importantly, this is the first evidence showing that TAX1BP1 can be as a novel regulatory target to attenuate the lung inflammation.
Activated leukocyte cell adhesion molecule (ALCAM) plays an important role in T cell activation and immune response, but the role of ALCAM in allergic rhinitis (AR) remains unclear. https://www.selleckchem.com/products/glumetinib.html The objective of the current study was to validate serum ALCAM as a biomarker in assessing disease severity and predicting the efficacy of sublingual immunotherapy (SLIT) in AR patients.
We recruited 40 healthy controls (HC group), 38 mild AR patients (MAR group) and 80 moderate-severe AR patients (MSAR group) in this study. Serum levels of ALCAM were determined by ELISA, and the association between ALCAM levels and disease severity was evaluated. In the MSAR group, 68 patients underwent and finished 3-years of SLIT, and were divided into effective group and ineffective group, the relationship between ALCAM levels and efficacy of SLIT was exampled.
ALCAM levels were elevated in the serum of AR patients in comparison with HC. Moreover, serum ALCAM concentrations were higher in MSAR group than in MAR group and HC group, and levels of ALCAM significantly correlated with AR total nasal symptom score (TNSS) (r = 0.330, P < 0.001), visual analogue scale (VAS) (r = 0.387, P < 0.001) and serum total IgE levels (r = 0.442, P < 0.001). In the effective group, the ALCAM levels were significantly lower than in the ineffective group. Receiver operating characteristic (ROC) curve exhibited good accuracy for predicting clinical efficacy of SLIT (area under the curve = 0.805, P < 0.001).
The serum ALCAM maybe a novel biomarker for assessing disease severity and predicting clinical efficacy of SLIT in AR patients.
The serum ALCAM maybe a novel biomarker for assessing disease severity and predicting clinical efficacy of SLIT in AR patients.
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and is responsible for 45-50% of primary glomerular diseases in China. We are essentially dependent on the degree of proteinuria to determine prognosis and it has been reported that histopathologic lesions are risk factors for the progression of IgAN. The aim of this study was to investigate the clinicopathologic features and prognosis of IgAN with C1q deposition in adult Chinese patients.
The patients of primary IgAN diagnosed by renal biopsy from January 2002 to December 2018 at the Second Hospital of Shanxi Medical University were retrospectively analyzed and divided into C1q deposit group and C1q negative group according to glomerular immunofluorescence examination. We evaluated their serologic and histopathologic findings. We collected data of patients during January 1, 2015 to December 31, 2018 and performed the clinical follow-up until the patient's estimated glomerular filtration rate (eGFR) decreased by more than 30unction and contributes to a poor renal prognosis in adult IgAN patients.
We aimed to study the effects and the underlying mechanisms of Diosmetin (DIOS) in rats with sepsis-induced acute kidney injury (AKI).
The AKI model in RMCs was induced using LPS, and the cells were then treated with DIOS. Cell viability, apoptosis, inflammatory response, and antioxidant were measured using MTT, Flow cytometry, ELISA, and Lucigenin assay, respectively. The correlation between TUG1 and Nrf2 was confirmed by RNA pull-down and RNA immunoprecipitation. Real-time quantitative PCR and Western blot were performed to detect the expressions of gene and proteins during the development of AKI. The effects of lncRNA-TUG1 silencing and Nrf2 silencing on cell physiological functions were detected. Moreover, a rat sepsis-induced AKI model followed by Hematoxylin & Eosin (H&E) and immunofluorescence staining were performed.
The experimental concentration of DIOS was determined to be 20μM. After LPS treatment, the activity of RMCs was decreased, the apoptosis rate, inflammation and oxidative stress damage were increased, moreover, the expression of Nrf2/HO-1 signal axis was inhibited and caspase-3 was activated. However, DIOS significantly reversed these effects caused by LPS treatment, and increased the expression of lncRNA-TUG1, but lncRNA-TUG1 silencing effectively reversed the effects of DIOS. In addition, lncRNA-TUG1 was found to interact with Nrf2. Overexpression of TUG1 could reduce the damage of LPS caused to cell physiological functions, which were reversed by siNrf2. Thus, DIOS treatment could improve the physiological and pathological damages of renal tissues in AKI rats.
DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.
DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.The present study aimed to investigate the protective effects and mechanisms of Didymin from Mentha spicata on non-alcoholic fatty liver disease (NAFLD) induced by dexamethasone and high-fat diet (DEX/HFD) in C57BL/6J mice. Briefly, mice were acclimated for 5 days and then subjected to DEX/HFD from days 5 to 28; meanwhile, the animals were treated with Didymin or Silibinin from days 12 to 28. Key indicators of NAFLD were then detected, including the pathological changes of liver tissues, serum biochemical indicators, inflammation, oxidative stress, apoptosis and lipid metabolism. Besides, the expressions of pivotal genes and proteins of the TLR4/NF-κB and PI3K/Akt pathways were examined to further elucidate the mechanisms of Didymin. The results demonstrated that Didymin significantly extenuated hepatocyte damage and lipid disorder. Moreover, Didymin markedly decreased hepatocyte apoptosis by regulating the expressions of B-cell lymphoma-2 (Bcl-2) family and the expressions of the caspase family. Further study elucidated that Didymin decreased the expressions of toll-like receptor 4 (TLR4), as well as the phosphorylation of inhibitor of nuclear factor kappa-B (IκB) and nuclear factor kappa-B p65 (NF-κB p65), suggesting the inhibition of Didymin on the TLR4/NF-κB pathway. Similarly, the PI3K/Akt pathway was also inhibited by Didymin, as evidenced by the decrease in the phosphorylation levels of PI3K and Akt. In summary, this study indicates that Didymin mitigates NAFLD by alleviating lipidosis and suppressing the TLR4/NF-κB and PI3K/Akt pathways, which may be a potential natural medicine for the treatment of NAFLD.
0 Commenti
0 condivisioni
8 Views
0 Anteprima
